Study of the Molecular Features of Postmenopausal Women With HR+ HER2-negative aBC on First-line Treatment With Ribociclib and Letrozole and, in Patients With a PIK3CA Mutation, on Second-line Treatment With Alpelisib Plus Fulvestrant
3상
조기 종료
NCT03439046
| 대상 질환 | Breast Cancer |
|---|
| 임상 단계 | 3상 |
|---|
| 스폰서 | Novartis Pharmaceuticals |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 287 명 |
|---|
| 중재(약물) | Ribociclib, Letrozole, Alpelisib, Fulvestrant |
|---|
| 시작일 | 2018년 2월 2일 |
|---|
| 완료일 | 2023년 12월 11일 |
|---|
| 결과 공개일 | 2026년 7월 10일 |
|---|
요약
The purpose of this clinical trial is to study of the molecular features of postmenopausal women with hormone receptor-positive (HR+) HER2-negative advanced breast cancer on first-line treatment with ribociclib and letrozole and, in patients with a PIK3CA mutation, on second-line treatment with alpelisib plus fulvestrant
Progression-Free Survival (PFS) by Cycle 1 Day 15 Complete Mutational Dynamic Change
Up to approximately 5.7 years · months
| Ribociclib+Letrozole (Core Phase) | 55.82 months |
|---|
| Ribociclib+Letrozole (Core Phase) | 16.53 months |
|---|
| Ribociclib+Letrozole (Core Phase) | 15.67 months |
|---|
| Ribociclib+Letrozole (Core Phase) | 22.44 months |
|---|
| Ribociclib+Letrozole (Core Phase) | 10.22 months |
|---|
| Ribociclib+Letrozole (Core Phase) | 11.07 months |
|---|
Number of Participants With Progression-Free Survival (PFS) Events by Cycle 1 Day 15 Complete Mutational Dynamic Change
Up to approximately 5.7 years · participants
| Ribociclib+Letrozole (Core Phase) | 31 participants |
|---|
| Ribociclib+Letrozole (Core Phase) | 13 participants |
|---|
| Ribociclib+Letrozole (Core Phase) | 6 participants |
|---|
| Ribociclib+Letrozole (Core Phase) | 28 participants |
|---|
| Ribociclib+Letrozole (Core Phase) | 6 participants |
|---|
| Ribociclib+Letrozole (Core Phase) | 10 participants |
|---|
Number of Participants With Hotspot Mutated Genes by Scheduled Timepoint
Up to approximately 5.7 years · participants
| Ribociclib+Letrozole (Core Phase) | 145 participants |
|---|
| Ribociclib+Letrozole (Core Phase) | 152 participants |
|---|
| Ribociclib+Letrozole (Core Phase) | 160 participants |
|---|
| Ribociclib+Letrozole (Core Phase) | 147 participants |
|---|
| Ribociclib+Letrozole (Core Phase) | 50 participants |
|---|
| Ribociclib+Letrozole (Core Phase) | 27 participants |
|---|
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.